Answers are grounded in this paper and cite their sources.
Dealing with dupilumab-induced hypereosinophilia represents a clinical challenge for clinicians managing patients on dupilumab therapy. An algorithm for the practical management of dupilumab-induced hypereosinophilia has been proposed, in order to properly investigate potential eosinophil-related morbidity and avoid unnecessary drug discontinuation.
No takes yet. Share an insight, caveat, or question.
Caminati et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: